ACELYRIN (SLRN) Stock

Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and additional phase 2 data by the end of 2024, potentially boosting shareholder value. Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events compared to other anti-IGF-1R therapies.

ACELRYN, INC. (Nasdaq: SLRN), a biopharmaceutical company specializing in advancing innovative medicines in immunology, will hold a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to review its financial results for the first quarter of 2024 and give a corporate update.

ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.

Acelyrin Inc shares slid as much as 11% in pre-market trading on Tuesday after the late-stage clinical biopharma company disclosed a programming error in its Phase 2b/3 drug trial for izokibep, a treatment for psoriatic arthritis.    Acelyrin said the protocol was programmed incorrectly by a vendor, "resulting in a sequencing error that went further unidentified through the providers' testing processes.

Acelyrin Inc. (NASDAQ:SLRN ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations, Communications, Corporate Operations Shao-Lee Lin - Founder, Chief Executive Officer and Director Gil Labrucherie - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Analyst, Piper Sandler Emily Bodnar - Analyst, H.C. Wainwright and Company Akash Tewari - Analyst, Jefferies Tyler Van Buren - TD Cowen Vikram Purohit - Morgan Stanley Operator Good day, and thank you for standing by.

Acelyrin's izokibep failed to meet statistical significance in its primary endpoint in a clinical trial evaluating the drug for the treatment of a skin inflammatory disorder. Shares of the biopharma company fell more than 50%, wiping out all of its post-IPO gains.

ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis suppurativa study of its lead candidate, izokibep. The stock of the company falls 54%.

Publicly traded since May, Acelyrin Inc (NASDAQ:SLRN) stock is plummeting to record lows today.

Acelyrin Inc (NASDAQ:SLRN) collapsed, down some 58% ahead of Tuesday's open, after the company revealed the failure of its clinical trial which attempted to reduce symptoms of inflammatory skin disease. The stock traded at its lowest point in its short history, following its May 2023 IPO which raised $540 million from investors who were effectively betting on the success of trials like this.